TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04062058

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: 45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOX
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery, preferred D2 lymphadenectomy
Study: NCT00708409

Intervention type: PROCEDURE
Intervention: Cardiac valve surgery
Description: Different autograft implantation techniques.

Intervention type: PROCEDURE
Intervention: Cardiac valve surgery
Description: Different autograft implantation techniques.
Study: NCT00060944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yondelis
Description: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yondelis
Description: 0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
Study: NCT03769571

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parental coaching program at ESDM (P-ESDM)
Description: It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
Study: NCT00060944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
Study: NCT03012750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Perioperative application of 0.1 mg ICG per kg Body weight
Study: NCT04158492

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard diagnostic procedures
Description: Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
Study: NCT00967616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS7017
Description: CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Description: FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Description: FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)
Study: NCT02543775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative SLN Mapping
Description: Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section.
Study: NCT03132818

Intervention type: OTHER
Intervention: To evaluate the prevalence of sexual disorders in patients receiving AMP
Description: To evaluate the prevalence of sexual disorders in patients receiving AMP

Intervention type: OTHER
Intervention: To evaluate the prevalence of sexual disorders in patients receiving AMP
Description: To evaluate the prevalence of sexual disorders in patients receiving AMP

Intervention type: OTHER
Intervention: To evaluate the prevalence of sexual disorders in patients receiving AMP
Description: To evaluate the prevalence of sexual disorders in patients receiving AMP
Study: NCT01815801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lungs were not mechanically ventilated during subclavian vein catheterization
Description: Control group
Study: NCT02202824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Description: Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
Study: NCT03145155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrating services for noncommunicable diseases in continuum of care for mothers and children
Description: The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary health education for pregnant women
Description: The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
Study: NCT00237770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-Nitro L-arginine-methylester (L-NAME)
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Head-up Tilt maneuver
Description: Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
Study: NCT00127855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT vaccine (MenHibrix)
Description: Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT vaccine (MenHibrix)
Description: Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MenCY-TT vaccine (MenHibrix)
Description: Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
Study: NCT01885793

Intervention type: DEVICE
Intervention: Cuffed endotracheal tube
Description: Intubation with a cuffed endotracheal tube (ETT).
Study: NCT01620034

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiotherapy
Description: Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
Study: NCT02176772

Intervention type: OTHER
Intervention: Stable iron isotopes, non-drug intervention
Study: NCT00006517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bright light box
Description: 10,000 lux bright light therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dawn simulator
Description: gradual rise in bedroom illumination prior to wake-up

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-output negative ion generator
Description: automated air ion delivery in bedroom prior to wake-up
Study: NCT00127855

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec®
Description: Three doses were administered IM in right lower thigh at Months 0,2 and 4.
Study: NCT00006517

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: low-output negative ion generator
Description: automated air ion delivery in bedroom prior to wake-up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dawn light pulse
Description: rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
Study: NCT03695536

Intervention type: BEHAVIORAL
Intervention: ultrasound use during resuscitation
Description: ultrasound use during resuscitation
Study: NCT00818805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1%
Description: one drop in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast 0.5%
Description: one drop in one eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Olopatadine)
Description: one drop in contralateral eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Tranilast)
Description: one drop in contralateral eye
Study: NCT01408849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maytenus ilicifolia leaves infusion
Description: 2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Standard therapy
Study: NCT03494881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucala
Description: All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
Study: NCT01188369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosimendan
Description: Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo drug
Description: Intravenous infusion, colour identical to levosimendan
Study: NCT04231721

Intervention type: DEVICE
Intervention: High Resolution Colonic Manometry and 3D-Transit system
Description: Measurement of colonic pressure changes and passage patterns in healthy.
Study: NCT03684044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo on Days 1, 4 and 7.
Study: NCT00418496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: 600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
Study: NCT03704727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10\^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10\^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10\^10 CFU/g Streptococcus thermophilus
Study: NCT01502969

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavin-M1
Description: liquid, 10e6ffu/dose, 2 doses, 2 month interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cell culture medium in absence of virus
Description: Placebo
Study: NCT01709357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle energy technique
Description: The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive stretching technique
Description: The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression technique
Description: The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham technique
Description: The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
Study: NCT05244161

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RMV-ECD
Description: Combined radio messaging, video job aids (primarily for CHWs), Care for Childhood Development package
Study: NCT02092181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: 25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
Study: NCT01470105

Intervention type: OTHER
Intervention: blood sampling, the SF-36 questionnaire
Description: The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit
Study: NCT01258673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan/HCTZ combination
Description: Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan 60mg, 120mg
Study: NCT01374425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 400 milligrams per meter-squared (mg/m\^2) by IV bolus and subsequent 2400 mg/m\^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/m\^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m\^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 850 or 1000 mg/m\^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
Study: NCT02655887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VENOVO™ Venous Stent
Description: VENOVO™ Venous stent placement
Study: NCT03279926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY
Description: Activity trackers + curriculum information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY
Description: Activity trackers + curriculum information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY
Description: Activity trackers + curriculum information

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Parents
Description: Enhanced parental engagement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY Teachers
Description: Enhanced teacher engagement with active living initiates for the teachers
Study: NCT01192880

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive bitopertin matching placebo once daily for 56 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Participants will receive 10 mg or 20 mg of bitopertin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Participants will receive 10 mg or 20 mg of bitopertin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipsychotics
Description: Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
Study: NCT02834819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Nebulized Hypertonic Saline
Study: NCT01146145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: intravenous morphine titration combined to ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intravenous morphine titration combined to ketamine
Study: NCT04534673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lambda 180 mcg S.C
Description: Prefilled injection syringe of 180 microgram Pegylated interferon lambda, administered on day 0 and if needed on day 7